BioSenic SA

New post-hoc analysis of our phase 2 clinical trial data suggests a repeated administration cycle for our upcoming phase 3 trial of oral arsenic trioxide (ATO) in chronic graft-versus-host disease (cGvHD). Read more 👉 lnkd.in/e7zaFr7K #arsenic #autoimmunity #gvhd

Press Release: @BioSenicSA publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis. To read more, visit: biosenic.com/sites/default/… #arsenictrioxide #systemicsclerosis

We are happy to provide an update regarding our current license agreement with Phebra. The maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023. 👉 lnkd.in/gwm9wEc4 #arsenic #CGvHD #ATO #biotech #SLE

We will host our Annual General Meeting on June 14 2023.  Preliminary documents for the Annual General Meeting have been made available on our website : lnkd.in/eyW8b7dW #medialresearch #scientificresearch #health #biotech #pharma #biopharma

We are pleased to anounce that we reacquired global IP rights and to provide update on JTA-004 development.   👉  lnkd.in/eRw97smw #viscosupplement #rheumatology #scientificresearch #osteoarthritis #paintreatment #health #biotech #clinicaltrial #biotech

We identified biomarkers for #cGvHD and submitted a #patent to EPO to cover a method to evaluate the potency of medications and allow the development of an industrial biomarker analysis kit which could generate a #turnover of 30 to 40 M euros globally. lnkd.in/eFr4FEd8

Last week, we announced 2022 full year results for 2022. : lnkd.in/gBA26uFM La semaine dernière nous avons présenté nos résultats pour l'année 2022. : lnkd.in/gkjFaVSb #finance #Biotech #health #innovation #immunity #celltherapy #ato

BioSenic new key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases with Arsenic-Copper biosenic.com/sites/default/… #patient #care #arsenic #copper #cancer #immunity #scientificresearch #health #biotech #research #patent

We now have an optimal combination of arsenic and copper to prevent autoimmunity in a murine model of systemic sclerosis. frontiersin.org/articles/10.33… #biosenic #SSc #arsenic #copper #cuivre #ROS #autoimmunity #immunity

🌍 Today we would like to highlight the importance of #biotechnology research in improving #health for all. We also salute the efforts of #healthcare professionals who work tirelessly to improve the quality of life for #patients. #WorldHealthDay #Research #AutoimmuneDiseases

We are pleased to welcome Lieven Huysse, MD as Chief Medical Officer.  lnkd.in/eAC6t-Pj #CMO #medialresearch #scientificresearch #health #biotech #clinicaltrial #pharma #biopharma

BioSenic publishes new data on the mechanism of action of arsenic trioxide lnkd.in/g3vBAx4b #arsenic #copper #systemicsclerosis #scientificresearch #health #biotech #research #autoimmunity #immunity

A Fenton-like cation can improve #arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice 👉ATO-Cu benefit to treat pathologies where activated cells are sensitive to oxidative stress. pubmed.ncbi.nlm.nih.gov/36016953/ #GvHD #copper #ROS #autoimmunity

Following the announcement of a new post-hoc analysis of our Phase III JTA-004 trial, boursier .com writes about us! More about it (in French) : boursier.com/actions/actual…

A new post-hoc analysis of our Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient open up further potential clinical development options for our viscosupplement. lnkd.in/ewPkAwnQ #osteoarthritis #paintreatment

Two weeks ago, we announced a statistical analysis optimization for our ALLOB Phase IIb study for high-risk tibial fractures. Fewer patients needed, significant time and costs reduction, analysis expected Q2 2023. lnkd.in/eTwWymMy #biosenic #celltherapy #health

We are delighted to welcome Dr Carole Nicco as Chief Scientific Officer. 📰 Find our press release here ➡ biosenic.com/news-events #autoimmunediseases #biotech #innovation #frenchtech

Phase II success for autoimmune disease platform in GVHD ddw-online.com/phase-ii-succe… #DrugDiscovery @BioSenicSA

"The promising response rates at six months justifies pursuing a phase III study, with a goal of broadening treatment options and reducing the overall morbidity of chronic GVHD in our transplant recipients." says Pr Corey Cutler ➡️ yhoo.it/3zVZN8H #gvhd #medtech #biotech

Our autoimmune disease platform based on ATO has completed a successful phase IIb trial targeting #cGVHD with a demonstrated efficacy of more than 75%.✅ Phase III is under preparation with expected accelerated examination by FDA. bit.ly/3NLntm8 #medtech #biotech